Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and Wuxi AppTec, JW Therapeutics is a leading cellular immunotherapy company with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors.

JW Therapeutics’ vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. The company has built a comprehensive and differentiated cell therapy pipeline covering both hematological cancers and solid tumors. Its lead product, relmacabtagene autoleucel (“relma-cel”), an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma, is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.